Cerepro, 400 mg capsules, 14 pcs.

Pharmacological action

Cerepro is a central cholinostimulant containing 40.5% metabolically protected choline (metabolic protection promotes choline release in the brain).

On entering the body it is split by the action of enzymes into choline and glycerophosphate: choline is involved in the biosynthesis of acetylcholine – one of the main mediators of neural excitation; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) of the neuronal membrane.

It provides synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation. Increases the linear velocity of blood flow on the side of the traumatic brain injury, promotes normalization of spatiotemporal characteristics of spontaneous bioelectrical activity of the brain; has a positive effect on the cognitive and behavioral responses of patients with cerebral vascular disease.

Cerepro improves brain function by acting on pathogenetic factors of involutional psychoorganic syndrome, changes phospholipid composition of neuronal membranes and reduces cholinergic activity. It dose-dependently stimulates acetylcholine release; participating in the synthesis of phosphahydylcholine (membrane phospholipid), improves synaptic transmission, neuronal membrane plasticity, receptor function. It does not influence the reproductive cycle and has no teratogenic and mutagenic effect.

Pharmacokinetics

Absorption – 88%), easily penetrates through the blood-brain barrier (with oral administration concentration in the brain – 45%) of that in plasma.) It is excreted mainly by lungs as carbon dioxide (85%) and also by the kidneys and intestines (15%).

Indications

Cerebral Circulatory Disorders, Mental Disorders, Aggression and Conflict, Acquired Dementia, Headache, Alzheimer’s Disease, Stroke Consequences, Attention and Memory Impairment

• Acute and recovery periods of severe traumatic brain injury and ischemic stroke, recovery period of hemorrhagic stroke, proceeding with focal hemispheric symptoms or symptoms of brainstem damage;
• psychoorganic syndrome against degenerative and involutionary changes of the brain;
• chronic insufficiency of cerebral circulation;
• Cognitive disorders (impairment of thinking function, memory, confusion, disorientation, decreased motivation, initiative and ability to concentrate) including in dementia and encephalopathy.
• Elderly pseudomelancholia.

.

Active ingredient

Choline alphoscerate

Composition

1 capsule contains:

acting substance:

400 mg glyceryl phosphorylcholine hydrate (choline alphosphocerate);

auxiliary substances:

glycerol (glycirin),

purified water.

Capsule shell:

gelatin medical,

glycerol (glycerin),

methyl parahydroxybenzoate (methylparaben),

propyl parahydroxybenzoate (propylparaben),

iron oxide red dye,

titanium dioxide,

purified water,

sorbitol (sorbitol).

How to take, the dosage

In acute conditions: intramuscularly or intravenously (slowly) 1.0 g (1 ampoule) per day for 10-15 days, then switch to taking capsules orally 0.8 g (2 capsules) in the morning and 0.4 g (1 capsule) during the day for 6 months.

In chronic conditions: orally 0.4 g (1 capsule) 3 times a day, preferably before meals. The duration of treatment is 3-6 months.

Special Instructions

If nausea occurs after taking the drug, the dose should be reduced. Cerepro has no effect on the speed of psychomotor reactions.

Contraindications

Hypersensitivity, pregnancy, breastfeeding.

.

Side effects

Allergic reactions, nausea (due to dopaminergic activation).

.

Similarities

Gliatilin, Cerepro, Cereton, Holitilin, Noocholin Rompharma, Choline alphoscerate